论文部分内容阅读
多发性骨髓瘤(multiple myeloma,MM)(WHO通用命名为浆细胞骨髓瘤)的治疗已进入了新药时代。近年来,新药物的广泛应用使得MM从曾经预期寿命很短的不治之症成为对治疗有持久反应的、潜在可控的疾病~([1-2]),患者的生存质量得以改善,生存时间明显延长~([3-4])。新检测技术的进步和应用,使MM患者的治疗、管控更加有效,新药的临床应用使得超过50%的MM患者在治疗后能够达到完全
The treatment of multiple myeloma (MM) (commonly referred to as plasma cell myeloma by WHO) has entered the new drug era. In recent years, the widespread use of new drugs has led MM to become a potentially manageable and potentially life-threatening condition for life-long refractory incurable diseases (1-2), improving quality of life and survival Time is significantly extended ~ ([3-4]). The progress and application of new detection technologies make the treatment and control of MM patients more effective. The clinical application of new drugs enables more than 50% of MM patients to achieve complete treatment after treatment